Drug-induced lupus erythematosus

M Pretel; L Marquès; A España

doi:10.1016/j.ad.2012.09.007

Drug-induced lupus erythematosus

Actas Dermosifiliogr. 2014 Jan-Feb;105(1):18-30. doi: 10.1016/j.ad.2012.09.007. Epub 2012 Nov 17.

[Article in English, Spanish]

Authors

M Pretel¹, L Marquès², A España²

Affiliations

¹ Departamento de Dermatología, Clínica Universidad de Navarra, Facultad de Medicina, Universidad de Navarra, Pamplona, España. Electronic address: mpretel@unav.es.
² Departamento de Dermatología, Clínica Universidad de Navarra, Facultad de Medicina, Universidad de Navarra, Pamplona, España.

PMID: 23164669
DOI: 10.1016/j.ad.2012.09.007

Abstract

Drug-induced lupus erythematosus (DILE) refers to a condition whose clinical, histological, and immunological features are similar to those seen in idiopathic lupus erythematosus but that occurs when certain drugs are taken and resolves after their withdrawal. Over 90 drugs have been linked to DILE to date and the list is growing. Like idiopathic lupus erythematosus, DILE has systemic, subacute cutaneous, and chronic cutaneous forms. A correct diagnosis is very important, as this condition usually resolves after withdrawal of the offending drug.

Keywords: Autoimmunity; Autoinmunidad; Drugs; Fármacos; Lupus; Lupus erythematosus.

Publication types

Review

MeSH terms

Autoimmunity
Biotransformation / immunology
Drug Substitution
Drug-Related Side Effects and Adverse Reactions / immunology
Genetic Predisposition to Disease
Humans
Lupus Erythematosus, Cutaneous / chemically induced*
Lupus Erythematosus, Cutaneous / diagnosis
Lupus Erythematosus, Cutaneous / epidemiology
Lupus Erythematosus, Cutaneous / immunology
Lupus Erythematosus, Systemic / chemically induced*
Lupus Erythematosus, Systemic / diagnosis
Lupus Erythematosus, Systemic / epidemiology
Lupus Erythematosus, Systemic / immunology
Pharmaceutical Preparations / classification
Symptom Assessment

Substances

Pharmaceutical Preparations